BIIB

Biogen's stock price has been influenced by several events in the past six months (April 2026 - October 2026). In April 2026, UBS upgraded Biogen due to anticipated pipeline catalysts for 2027. The company's acquisition of Apellis Pharmaceuticals, announced in March 2026 and closed in May, strengthened its immunology portfolio. By July 4, 2026, news indicated that Biogen's shift towards growth products resulted in a 12% increase in sales for these drugs in the first quarter. However, on July 14, 2026, Biogen's stock dropped 7% following detailed results from a mid-stage study of its experimental Alzheimer's drug, diranersen, which raised concerns. Later in July, on the 29th, Biogen reported better-than-expected Q2 CY2026 results, with revenue up 3.4% year-on-year and adjusted EPS significantly surpassing estimates, leading to raised full-year guidance. In August 2026, the LEQEMBI IQLIK® autoinjector became available in the U.S. for early Alzheimer's therapy. By September 3, 2026, Morningstar highlighted Biogen's efforts to reposition its portfolio to offset declining revenues, emphasizing its strong neurodegenerative and rare disease pipeline. More recently, on October 5, 2026, despite a slight dip, analyst sentiment remained largely positive with a majority of 'buy' ratings. As of October 9, 2026, Biogen shares rose 3.3% and were trading near their 52-week high, reflecting a 50.9% increase over the past year.